Development of matrix metalloproteinase inhibitors in cancer therapy.
暂无分享,去创建一个
[1] S. Steinberg,et al. Phase I clinical trial of oral COL-3, a matrix metalloproteinase inhibitor, in patients with refractory metastatic cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] Timo Sorsa,et al. Tumor targeting with a selective gelatinase inhibitor , 1999, Nature Biotechnology.
[3] J. Smyth,et al. Phase I study of intraperitoneal metalloproteinase inhibitor BB94 in patients with malignant ascites. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.
[4] W. Stetler-Stevenson,et al. Matrix metalloproteinases and metastasis , 1999, Cancer Chemotherapy and Pharmacology.
[5] F. C. Nelson,et al. Design and Synthetic Considerations of Matrix Metalloproteinase Inhibitors , 1999, Annals of the New York Academy of Sciences.
[6] J. Fata,et al. Host TIMP-1 overexpression confers resistance to experimental brain metastasis of a fibrosarcoma cell line , 1998, Oncogene.
[7] J. Verheijen,et al. Determination of Gelatinase‐A (MMP‐2) Activity Using a Novel Immunocapture Assay , 1999, Annals of the New York Academy of Sciences.
[8] G. Taraboletti,et al. Batimastat, a synthetic inhibitor of matrix metalloproteinases, potentiates the antitumor activity of cisplatin in ovarian carcinoma xenografts. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.
[9] K. Reddy,et al. Mitogen‐activated protein kinase (MAPK) regulates the expression of progelatinase B (MMP‐9) in breast epithelial cells , 1999, International journal of cancer.
[10] A. H. Drummond,et al. Preclinical and Clinical Studies of MMP Inhibitors in Cancer , 1999, Annals of the New York Academy of Sciences.
[11] W. Stetler-Stevenson,et al. Marked acceleration of the metastatic phenotype of a rat bladder carcinoma cell line by the expression of human gelatinase a , 1995, International journal of cancer.
[12] A. Rafe,et al. TIMP-2 growth-stimulatory activity: a concentration- and cell type-specific response in the presence of insulin. , 1996, Experimental cell research.
[13] A. Stoppacciaro,et al. Inhibition of the metastatic spread and growth of B16‐BL6 murine melanoma by a synthetic matrix metalloproteinase inhibitor , 1994, International journal of cancer.
[14] D. Lauffenburger,et al. Metalloprotease-mediated ligand release regulates autocrine signaling through the epidermal growth factor receptor. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[15] M Nakajima,et al. [Matrix metalloproteinase inhibitors]. , 2000, Tanpakushitsu kakusan koso. Protein, nucleic acid, enzyme.
[16] J. Folkman. Seminars in Medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis. , 1995, The New England journal of medicine.
[17] G. Hortobagyi,et al. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group. , 1996, The New England journal of medicine.
[18] W. A. Galloway,et al. Results of single and repeat dose studies of the oral matrix metalloproteinase inhibitor marimastat in healthy male volunteers. , 1998, British journal of clinical pharmacology.
[19] F. Balkwill,et al. A synthetic matrix metalloproteinase inhibitor decreases tumor burden and prolongs survival of mice bearing human ovarian carcinoma xenografts. , 1993, Cancer research.
[20] Y. Itoh,et al. MEMBRANE-TYPE MATRIX METALLOPROTEINASES , 2017 .
[21] G. Butler,et al. The Soluble Catalytic Domain of Membrane Type 1 Matrix Metalloproteinase Cleaves the Propeptide of Progelatinase A and Initiates Autoproteolytic Activation , 1996, The Journal of Biological Chemistry.
[22] M. Polette,et al. Expression of matrix metalloproteinases and their inhibitors in human bronchopulmonary carcinomas: Quantificative and morphological analyses , 1997, International journal of cancer.
[23] J. Roh,et al. Different expression patterns of MMP-2 and MMP-9 in breast cancer. , 1998, Oncology reports.
[24] B. Nielsen,et al. Cancer invasion and tissue remodeling‐cooperation of protease systems and cell types , 1999, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.
[25] T. Morris,et al. Inhibition of organ invasion by the matrix metalloproteinase inhibitor batimastat (BB-94) in two human colon carcinoma metastasis models. , 1995, Cancer research.
[26] B. Fingleton,et al. Matrix metalloproteinases: biologic activity and clinical implications. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] B. Lokeshwar,et al. MMP Inhibition in Prostate Cancer , 1999, Annals of the New York Academy of Sciences.
[28] Daniel,et al. There are no bad anticancer agents, only bad clinical trial designs--twenty-first Richard and Hinda Rosenthal Foundation Award Lecture. , 1998 .
[29] W. Stetler-Stevenson,et al. Elevated tissue inhibitor of metalloproteinase 1 RNA in colorectal cancer stroma correlates with lymph node and distant metastases. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.
[30] L. Matrisian,et al. Changing views of the role of matrix metalloproteinases in metastasis. , 1997, Journal of the National Cancer Institute.
[31] N. Block,et al. CMT‐3, a Chemically Modified Tetracycline, Inhibits Bony Metastases and Delays the Development of Paraplegia in a Rat Model of Prostate Cancer , 1999, Annals of the New York Academy of Sciences.
[32] L. Matrisian,et al. Measurement of Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases in Blood and Tissues: Clinical and Experimental Applications , 1999, Annals of the New York Academy of Sciences.
[33] H. Ronday,et al. Fluorogenic MMP Activity Assay for Plasma Including MMPs Complexed to α2‐Macroglobulin , 1999 .
[34] Y. Okada,et al. Stimulation of gelatinase B and tissue inhibitors of metalloproteinase (TIMP) production in co‐culture of human osteosarcoma cells and human fibroblasts: Gelatinase‐B production was stimulated via up‐regulation of fibroblast growth factor (FGF) receptor , 1996, International journal of cancer.
[35] G. Nuovo. In situ detection of PCR‐amplified metalloproteinase cDNAS, their inhibitors and human papillomavirus transcripts in cervical carcinoma cell lines , 1997, International journal of cancer.
[36] Cornelis F. M. Sier,et al. MMP‐9 Activity in Urine from Patients with Various Tumors, as Measured by a Novel MMP Activity Assay Using Modified Urokinase as a Substrate , 1999, Annals of the New York Academy of Sciences.
[37] R. Khokha,et al. Overexpression of metalloproteinase inhibitor in B16F10 cells does not affect extravasation but reduces tumor growth. , 1994, Cancer research.
[38] M. Feldmann,et al. Paradoxical effects of a synthetic metalloproteinase inhibitor that blocks both p55 and p75 TNF receptor shedding and TNF alpha processing in RA synovial membrane cell cultures. , 1996, The Journal of clinical investigation.
[39] K. Brandt,et al. Specificity of inhibition of matrix metalloproteinase activity by doxycycline: relationship to structure of the enzyme. , 1999, Arthritis and rheumatism.
[40] A. Harris,et al. Phase I and pharmacological study of the oral matrix metalloproteinase inhibitor, MMI270 (CGS27023A), in patients with advanced solid cancer. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[41] M. Turner,et al. Drug-induced lupus associated with COL-3: report of 3 cases. , 2001, Archives of Dermatology.
[42] D. Gomez,et al. Mammary carcinoma cells over-expressing tissue inhibitor of metalloproteinases-1 show enhanced vascular endothelial growth factor expression. , 1998, International journal of cancer.
[43] G. Sledge,et al. Effect of matrix metalloproteinase inhibitor batimastat on breast cancer regrowth and metastasis in athymic mice. , 1995, Journal of the National Cancer Institute.
[44] M. Selman,et al. 72-kD (MMP-2) and 92-kD (MMP-9) Type IV Collagenase Production and Activity in Different Histologic Types of Lung Cancer Cells , 1998, Pathobiology.
[45] L. Ding,et al. Controlling tumor angiogenesis and metastasis of C26 murine colon adenocarcinoma by a new matrix metalloproteinase inhibitor, KB-R7785, in two tumor models. , 1999, Cancer research.
[46] V. Kähäri,et al. Adenovirus-mediated gene delivery of tissue inhibitor of metalloproteinases-3 inhibits invasion and induces apoptosis in melanoma cells. , 1998, Cancer research.
[47] J. Nemunaitis,et al. Combined analysis of studies of the effects of the matrix metalloproteinase inhibitor marimastat on serum tumor markers in advanced cancer: selection of a biologically active and tolerable dose for longer-term studies. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.
[48] P. Delmas. Bisphosphonates in the treatment of bone diseases. , 1996, The New England journal of medicine.
[49] Bill Broyles. Notes , 1907, The Classical Review.
[50] L. Golub,et al. Tetracyclines inhibit tissue collagenase activity. A new mechanism in the treatment of periodontal disease. , 1984 .
[51] C. Rossi,et al. Inhibition of gelatinase A (MMP‐2) by batimastat and captopril reduces tumor growth and lung metastases in mice bearing Lewis lung carcinoma , 1999, International journal of cancer.
[52] Y. Okada,et al. Expression of membrane-type matrix metalloproteinase 1 (MT1-MMP) in tumor cells enhances pulmonary metastasis in an experimental metastasis assay. , 1996, Cancer research.
[53] J. Netterville,et al. Expression of Matrix Metalloproteinases and Tissue Inhibitor of Metalloproteinases in Head and Neck Squamous Cell Carcinoma , 1997, The Annals of otology, rhinology, and laryngology.
[54] K. Hess,et al. Phase II trial of temozolomide plus the matrix metalloproteinase inhibitor, marimastat, in recurrent and progressive glioblastoma multiforme. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[55] W. Bode,et al. 1.8-A crystal structure of the catalytic domain of human neutrophil collagenase (matrix metalloproteinase-8) complexed with a peptidomimetic hydroxamate primed-side inhibitor with a distinct selectivity profile. , 1997, European journal of biochemistry.
[56] B. Winograd,et al. Promising new developments in cancer chemotherapy , 1999, Cancer Chemotherapy and Pharmacology.
[57] Charles D. McDermott,et al. Marked antiangiogenic and antitumor efficacy of AG3340 in chemoresistant human non-small cell lung cancer tumors: single agent and combination chemotherapy studies. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.
[58] H. Radzun,et al. Expression of metalloproteinase 2 and 9 and their inhibitors in renal cell carcinoma. , 1998, The Journal of urology.
[59] M. Abrahamowicz,et al. Randomized discontinuation trials: utility and efficiency. , 1993, Journal of clinical epidemiology.
[60] D. Gomez,et al. Enhanced RNA expression of tissue inhibitor of metalloproteinases‐1 (TIMP‐1) in human breast cancer , 1996, International journal of cancer.
[61] R. Khokha,et al. Inhibition of SV40 T antigen-induced hepatocellular carcinoma in TIMP-1 transgenic mice. , 1996, Oncogene.
[62] W. Li,et al. Up‐regulation of tissue inhibitor of metalloproteinases‐3 gene expression by TGF‐β in articular chondrocytes is mediated by serine/threonine and tyrosine kinases , 1998, Journal of cellular biochemistry.
[63] W. Steward. Marimastat (BB2516): Current status of development , 1999, Cancer Chemotherapy and Pharmacology.
[64] D. Gomez,et al. Mammary carcinoma cells over‐expressing tissue inhibitor of metalloproteinases‐1show vascular endothelial growth factor expression , 1998 .
[65] J. McKay,et al. Matrix metalloproteinase‐1 is associated with poor prognosis in oesophageal cancer , 1998, The Journal of pathology.
[66] D. Boyd,et al. Inhibition of the p38 mitogen-activated protein kinase by SB 203580 blocks PMA-induced Mr 92,000 type IV collagenase secretion and in vitro invasion. , 1998, Cancer research.
[67] G. Sledge,et al. Effects of doxycycline on human prostate cancer cells in vitro. , 1998, Cancer letters.
[68] T. Ishikawa,et al. Matrilysin‐specific antisense oligonucleotide inhibits liver metastasis of human colon cancer cells in a nude mouse model , 1998, International journal of cancer.
[69] Y. Okada,et al. Membrane-Type Matrix Metalloproteinases (MT-MMPs) in Cell Invasion , 1997, Thrombosis and Haemostasis.
[70] K. Tatsumi,et al. Inhibition of Spontaneous Rat Osteosarcoma Lung Metastasis by 3S‐[4‐(Nhydroxyamino)‐2R‐isobutylsuccinyl]amino‐1‐methoxy‐3,4‐dihydrocarbostyril, a Novel Matrix Metalloproteinase Inhibitor , 1999, Japanese journal of cancer research : Gann.
[71] E. Scanziani,et al. Inhibition of angiogenesis and murine hemangioma growth by batimastat, a synthetic inhibitor of matrix metalloproteinases. , 1995, Journal of the National Cancer Institute.
[72] L. Golub,et al. In vitro sensitivity of the three mammalian collagenases to tetracycline inhibition: relationship to bone and cartilage degradation. , 1998, Bone.
[73] H. Yamamoto,et al. Association of matrilysin expression with recurrence and poor prognosis in human esophageal squamous cell carcinoma. , 1999, Cancer research.
[74] S. Shapiro,et al. Matrix metalloproteinase degradation of extracellular matrix: biological consequences. , 1998, Current opinion in cell biology.
[75] W. Stetler-Stevenson,et al. Gelatinase A activity directly modulates melanoma cell adhesion and spreading. , 1995, The EMBO journal.
[76] R. Khokha,et al. Insulin-like Growth Factor II Signaling in Neoplastic Proliferation Is Blocked by Transgenic Expression of the Metalloproteinase Inhibitor Timp-1 , 1999, The Journal of cell biology.
[77] H. Tsuzuki,et al. Correlation of antiangiogenic and antitumor efficacy of N-biphenyl sulfonyl-phenylalanine hydroxiamic acid (BPHA), an orally-active, selective matrix metalloproteinase inhibitor. , 1999, Cancer research.
[78] H. Hirte,et al. Use of tetracycline as an inhibitor of matrix metalloproteinase activity secreted by human bone-metastasizing cancer cells. , 1997, Invasion & metastasis.
[79] L. Golub,et al. Matrix metalloproteinases and their inhibition in periodontal treatment. , 1996, Current opinion in periodontology.
[80] T. Salo,et al. MMP Inhibition and Downregulation by Bisphosphonates , 1999, Annals of the New York Academy of Sciences.
[81] T. Kubota,et al. Preventive Effect of Matrix Metalloproteinase Inhibitor, R‐94138, in Combination with Mitomycin C or Cisplatin on Peritoneal Dissemination of Human Gastric Cancer Cell Line TMK‐1 in Nude Mice , 1999, Japanese journal of cancer research : Gann.
[82] M. Stearns,et al. IL-10 inhibition of human prostate PC-3 ML cell metastases in SCID mice: IL-10 stimulation of TIMP-1 and inhibition of MMP-2/MMP-9 expression. , 1997, Invasion & metastasis.
[83] J. Yagüe,et al. Fibronectin upregulates gelatinase B (MMP-9) and induces coordinated expression of gelatinase A (MMP-2) and its activator MT1-MMP (MMP-14) by human T lymphocyte cell lines. A process repressed through RAS/MAP kinase signaling pathways. , 1999, Blood.
[84] C. López-Otín,et al. Regulation of collagenase-3 expression in human breast carcinomas is mediated by stromal-epithelial cell interactions. , 1997, Cancer research.
[85] T. Okubo,et al. Inhibition of tumor promoter activity toward mouse fibroblasts and their in vitro transformation by tissue inhibitor of metalloproteinases-1 (TIMP-1). , 1997, Carcinogenesis.
[86] G. Stamp,et al. Imbalance of expression of matrix metalloproteinases (MMPs) and tissue inhibitors of the matrix metalloproteinases (TIMPs) in human pancreatic carcinoma , 1997, The Journal of pathology.
[87] J. Marshall,et al. Phase I trial of Marimastat, a novel matrix metalloproteinase inhibitor, administered orally to patients with advanced lung cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[88] R. Fridman,et al. Epidermal growth factor and amphiregulin up‐regulate matrix metalloproteinase‐9 (MMP‐9) in human breast cancer cells , 1997, International journal of cancer.
[89] H. Zou,et al. Marked inhibition of tumor growth in a malignant glioma tumor model by a novel synthetic matrix metalloproteinase inhibitor AG3340. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.
[90] J. Rhim,et al. Interleukin 10 (IL-10) inhibition of primary human prostate cell-induced angiogenesis: IL-10 stimulation of tissue inhibitor of metalloproteinase-1 and inhibition of matrix metalloproteinase (MMP)-2/MMP-9 secretion. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.
[91] W. Bode,et al. Endoproteinase‐protein inhibitor interactions , 1999, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.
[92] T. Salo,et al. Expression of matrix metalloproteinases (MMP-1 and -2) and their inhibitors (TIMP-1, -2 and -3) in oral lichen planus, dysplasia, squamous cell carcinoma and lymph node metastasis. , 1998, British Journal of Cancer.
[93] R. A. Lacalle,et al. Insulin-Like Growth Factor I-Triggered Cell Migration and Invasion Are Mediated by Matrix Metalloproteinase-9. , 1999, Endocrinology.
[94] Jack P. Witty,et al. Expression and localization of matrix‐degrading metalloproteinases during colorectal tumorigenesis , 1994, Molecular carcinogenesis.
[95] M. Stack,et al. Proteinase requirements of epidermal growth factor–induced ovarian cancer cell invasion , 1998, International journal of cancer.
[96] R. Kerbel,et al. ‘Proteolytic switching’: opposite patterns of regulation of gelatinase B and its inhibitor TIMP-1 during human melanoma progression and consequences of gelatinase B overexpression , 1999, British Journal of Cancer.
[97] D. Powe,et al. TIMP-3 mRNA expression is regionally increased in moderately and poorly differentiated colorectal adenocarcinoma. , 1997, British Journal of Cancer.
[98] Charles D. McDermott,et al. Broad Antitumor and Antiangiogenic Activities of AG3340, a Potent and Selective MMP Inhibitor Undergoing Advanced Oncology Clinical Trials , 1999, Annals of the New York Academy of Sciences.
[99] B. Hogan,et al. Intestinal tumorigenesis is suppressed in mice lacking the metalloproteinase matrilysin. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[100] A. Karameris,et al. Association of expression of metalloproteinases and their inhibitors with the metastatic potential of squamous-cell lung carcinomas. A molecular and immunohistochemical study. , 1997, American journal of respiratory and critical care medicine.
[101] M. Dardenne. Role of thymic peptides as transmitters between the neuroendocrine and immune systems. , 1999, Annals of medicine.
[102] R. Grenman,et al. Expression of collagenase-3 (matrix metalloproteinase-13) in squamous cell carcinomas of the head and neck. , 1997, The American journal of pathology.
[103] B. Davidson,et al. Expression of Metalloproteinases and Their Inhibitors in Adenocarcinoma of the Uterine Cervix , 1998, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.
[104] B. Fingleton,et al. Matrilysin in early stage intestinal tumorigenesis , 1999, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.
[105] R. Hoffman,et al. Matrix metalloproteinase inhibitor BB-94 (batimastat) inhibits human colon tumor growth and spread in a patient-like orthotopic model in nude mice. , 1994, Cancer research.
[106] J. Keski‐Oja,et al. Expression of collagenases-1 and -3 and their inhibitors TIMP-1 and -3 correlates with the level of invasion in malignant melanomas , 1999, British Journal of Cancer.
[107] John E. Fothergill,et al. Matrix metalloproteinase–1 is associated with poor prognosis in colorectal cancer , 1996, Nature Medicine.
[108] G. Nicolson,et al. Effect of PD 098059, a specific inhibitor of mitogen-activated protein kinase kinase, on urokinase expression and in vitro invasion. , 1996, Cancer research.
[109] P. D. Brown,et al. A phase II trial of marimastat in advanced pancreatic cancer , 2001, British Journal of Cancer.
[110] E. Rosenthal,et al. Role of the plasminogen activator and matrix metalloproteinase systems in epidermal growth factor- and scatter factor-stimulated invasion of carcinoma cells. , 1998, Cancer research.
[111] H. Tsuzuki,et al. Highly selective and orally active inhibitors of type IV collagenase (MMP-9 and MMP-2): N-sulfonylamino acid derivatives. , 1998, Journal of medicinal chemistry.
[112] V. Kähäri,et al. Matrix metalloproteinases and their inhibitors in tumour growth and invasion. , 1999, Annals of medicine.
[113] A. Harris,et al. Anticancer agents targeting signaling molecules and cancer cell environment: challenges for drug development? , 1999, Journal of the National Cancer Institute.
[114] G. Sledge,et al. Effects of doxycycline on in vitro growth, migration, and gelatinase activity of breast carcinoma cells. , 1995, The Journal of laboratory and clinical medicine.
[115] E. Abel. Clinical applications of research on angiogenesis , 1996 .
[116] B. Achinstein,et al. Journal of the National Cancer Institute, Vol. 29, 1962: Action of bacterial polysaccharide on tumors. II. Damage of sarcoma 37 by serum of mice treated with Serratia marcescens polysaccharide, and induced tolerance. , 2009, Nutrition reviews.
[117] P. Zimmerman,et al. TIMP1 and adverse prognosis in non-small cell lung cancer. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.
[118] S. Ye,et al. Effects of matrix metalloproteinase inhibitor BB-94 on liver cancer growth and metastasis in a patient-like orthotopic model LCI-D20. , 1998, Hepato-gastroenterology.
[119] Y. Kihira,et al. Expression of matrix metalloproteinase-7 and tissue inhibitor of metalloproteinase-1 in human prostate. , 1998, The Journal of urology.
[120] J. Rozmus,et al. Growth factors and cytokines upregulate gelatinase expression in bone marrow CD34(+) cells and their transmigration through reconstituted basement membrane. , 1999, Blood.
[121] D. Benezra. Inhibition of angiogenesis by tissue inhibitor of metalloproteinase-3. , 1997, Investigative ophthalmology & visual science.
[122] D. Gomez,et al. Tissue inhibitors of metalloproteinases: structure, regulation and biological functions. , 1997, European journal of cell biology.
[123] E. Eisenhauer,et al. Phase I and II trials of novel anti-cancer agents: endpoints, efficacy and existentialism. The Michel Clavel Lecture, held at the 10th NCI-EORTC Conference on New Drugs in Cancer Therapy, Amsterdam, 16-19 June 1998. , 1998, Annals of oncology : official journal of the European Society for Medical Oncology.
[124] H. Ronday,et al. Fluorogenic MMP activity assay for plasma including MMPs complexed to alpha 2-macroglobulin. , 1999, Annals of the New York Academy of Sciences.
[125] N. Hooper,et al. Membrane protein secretases. , 1997, The Biochemical journal.
[126] S. Eccles,et al. Control of lymphatic and hematogenous metastasis of a rat mammary carcinoma by the matrix metalloproteinase inhibitor batimastat (BB-94). , 1996, Cancer research.
[127] P. Henriet,et al. Tissue inhibitors of metalloproteinases (TEMP) in invasion and proliferation , 1999, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.
[128] M. Duffy,et al. High levels of tissue inhibitor of metalloproteinase‐1 predict poor outcome in patients with breast cancer , 1999, International journal of cancer.
[129] A. Rosemurgy,et al. Matrix metalloproteinase inhibition attenuates human pancreatic cancer growth in vitro and decreases mortality and tumorigenesis in vivo. , 1997, The Journal of surgical research.
[130] G. Butler,et al. Mechanisms for pro matrix metalloproteinase activation , 1999, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.
[131] R. Nagle,et al. EGF induces the expression of matrilysin in the human prostate adenocarcinoma cell line, LNCaP , 1999, The Prostate.
[132] J. D. Petke,et al. Solution structures of stromelysin complexed to thiadiazole inhibitors , 1998, Protein science : a publication of the Protein Society.
[133] Y. Okada,et al. Production of Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases in Human Breast Carcinomas , 1996, Japanese journal of cancer research : Gann.
[134] G. Sledge,et al. Inhibition of proliferation and induction of apoptosis by doxycycline in cultured human osteosarcoma cells. , 1997, The Journal of laboratory and clinical medicine.
[135] S. Itohara,et al. Reduced angiogenesis and tumor progression in gelatinase A-deficient mice. , 1998, Cancer research.
[136] A. Doherty,et al. In vitro pharmacological characterization of PD 166285, a new nanomolar potent and broadly active protein tyrosine kinase inhibitor. , 1997, The Journal of pharmacology and experimental therapeutics.
[137] M. Barbacid,et al. Identification of Insulin-like Growth Factor-binding Protein-1 as a Potential Physiological Substrate for Human Stromelysin-3* , 1997, The Journal of Biological Chemistry.
[138] M. Bissell,et al. An odyssey from breast to bone: Multi‐step control of mammary metastases and osteolysis by matrix metalloproteinases , 1999, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.
[139] A. Rosemurgy,et al. Marimastat as first-line therapy for patients with unresectable pancreatic cancer: a randomized trial. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[140] A. Harris,et al. Phase I study of intrapleural batimastat (BB-94), a matrix metalloproteinase inhibitor, in the treatment of malignant pleural effusions. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.
[141] M. Rudek,et al. Reversible sideroblastic anemia associated with the tetracycline analogue COL‐3 , 2001, American journal of hematology.
[142] T M Grogan,et al. Expression of the metalloproteinase matrilysin in DU-145 cells increases their invasive potential in severe combined immunodeficient mice. , 1993, Cancer research.
[143] O. Yoshida,et al. Role of matrix metalloproteinase-9 in the basement membrane destruction of superficial urothelial carcinomas. , 1999, The Journal of urology.
[144] L. Matrisian,et al. Expression of most matrix metalloproteinase family members in breast cancer represents a tumor-induced host response. , 1996, The American journal of pathology.
[145] M. Mitchell,et al. Synthetic matrix metalloproteinase inhibitors and tissue inhibitor of metalloproteinase (TIMP)-2, but not TIMP-1, inhibit shedding of tumor necrosis factor-alpha receptors in a human colon adenocarcinoma (Colo 205) cell line. , 1998, Cancer research.
[146] R. Muschel,et al. Inhibition of matrix metalloproteinase 9 expression by a ribozyme blocks metastasis in a rat sarcoma model system. , 1996, Cancer research.
[147] R. Dickson,et al. The matrix metalloproteinase inhibitor batimastat (BB-94) retards human breast cancer solid tumor growth but not ascites formation in nude mice. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.
[148] D. Kerr,et al. Phase I clinical trial of the flavonoid quercetin: pharmacokinetics and evidence for in vivo tyrosine kinase inhibition. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.
[149] F. Aoudjit,et al. Bi-directional induction of matrix metalloproteinase-9 and tissue inhibitor of matrix metalloproteinase-1 during T lymphoma/endothelial cell contact: implication of ICAM-1. , 1998, Journal of immunology.
[150] E. Casper,et al. Marimastat in patients with advanced pancreatic cancer: a dose-finding study. , 1999, American journal of clinical oncology.
[151] P. Brown. Clinical studies with matrix metalloproteinase inhibitors , 1999, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.
[152] M. Hidalgo,et al. Phase I and pharmacologic study of the specific matrix metalloproteinase inhibitor BAY 12-9566 on a protracted oral daily dosing schedule in patients with solid malignancies. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[153] G. Rodan,et al. Bisphosphonates: mechanisms of action , 1998, Endocrine reviews.
[154] N. Colburn,et al. Suppression of in vivo tumor growth and induction of suspension cell death by tissue inhibitor of metalloproteinases (TIMP)-3. , 1996, Carcinogenesis.
[155] S. Gruber,et al. Direct evidence linking expression of matrix metalloproteinase 9 (92-kDa gelatinase/collagenase) to the metastatic phenotype in transformed rat embryo cells. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[156] J. Foidart,et al. In Vivo Evidence That the Stromelysin-3 Metalloproteinase Contributes in a Paracrine Manner to Epithelial Cell Malignancy , 1998, The Journal of cell biology.